J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
|
|
- Elmer Griffin
- 7 years ago
- Views:
Transcription
1 VOLUME 26 NUMBER 18 JUNE JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt- Münster (ALL-BFM) Trials Andishe Attarbaschi, Georg Mann, Renate Panzer-Grümayer, Silja Röttgers, Manuel Steiner, Margit König, Eva Csinady, Michael N. Dworzak, Markus Seidel, Dasa Janousek, Anja Möricke, Carsten Reichelt, Jochen Harbott, Martin Schrappe, Helmut Gadner, and Oskar A. Haas From the Department of Pediatric Hematology and Oncology, St Anna Children s Hospital; the Children s Cancer Research Institute, Vienna, Austria; the Department of Pediatric Hematology and Oncology, Justus- Liebig-University, Giessen; and the Department of Pediatric Hematology and Oncology, Children s University Hospital, University Hospital Schleswig- Holstein, Campus Kiel, Germany. Submitted January 5, 2008; accepted March 17, Supported by the Deutsche Krebshilfe; the Österreichische Kinderkrebshilfe; the Research Program, Genome Research for Health of the Austrian Ministry of Education, Science, and Culture (Grants No. GZ /3-VI/2a/ 2002, and GZ /1-VI/1/2005); and the Fonds zur Förderung der wissenschaftlichen Forschung (FWF Grants No. P15150 and P17551B14). Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Corresponding author: Oskar A. Haas, MD, St Anna Children s Hospital, Kinderpitalgasse 6,Vienna, Austria, 1090; oskar.haas@stanna.at by American Society of Clinical Oncology A B S T R A C T Purpose We aimed to identify relapse predictors in children with a B-cell precursor acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iamp21), a novel genetic entity associated with poor outcome. Patients and Methods We screened 1,625 patients who were enrolled onto the Austrian and German ALL Berlin- Frankfurt-Münster (ALL-BFM) trials 86, 90, 95, and 2000 with ETV6/RUNX1-specific fluorescent in situ hybridization probes, and we identified 29 patient cases (2%) who had an iamp21. Minimal residual disease (MRD) was quantified with clone-specific immunoglobulin and T-cell receptor gene rearrangements. Results Twenty-five patients were good responders to prednisone, and all achieved remission after induction therapy. Eleven patients experienced relapse, which included eight who experienced relapse after cessation of front-line therapy. Six-year event-free and overall survival rates were 37% 14% and 66% 11%, respectively. Results of MRD analysis were available in 24 (83%) of 29 patients: nine (37.5%) belonged to the low-risk, 14 (58.5%) to the intermediate-risk, and one (4%) to the high-risk group. MRD results were available in 8 of 11 patients who experienced a relapse. Seven occurred among the 14 intermediate-risk patients, and one occurred in the high-risk patient. Conclusion The overall and early relapse rates in the BFM study were lower than that in a previous United Kingdom Medical Research Council/Childhood Leukemia Working Party study (38% v 61% and 27% v 47%, respectively), which might result from more intensive induction and early reintensification therapy in the ALL-BFM protocols. MRD values were the only reliable parameter to discriminate between a low and high risk of relapse (P.02). J Clin Oncol 26: by American Society of Clinical Oncology X/08/ /$20.00 DOI: /JCO INTRODUCTION Recently, the United Kingdom National Cancer Research Institute (NCRI) Childhood Leukemia Working Party (CLWP) reported a novel genetic entity in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is characterized by an intrachromosomal amplification of chromosome 21 (iamp21). 1,2 Its common defining feature is the presence of multiple copies of the RUNX1 gene that are usually contained within a morphologically abnormal chromosome 21. This gene amplification was identified by chance during fluorescent in situ hybridization (FISH) screening for ETV6/RUNX1- positive ALL; so far, FISH analysis also remains the only reliable method to identify such occurrences of ALL with an iamp21. The United Kingdom CLWP also provided the first demographic, clinical, and survival data for this specific entity. 2 The results indicated a significantly inferior survival of patients by American Society of Clinical Oncology
2 MRD-Dependent Relapse Risk of Childhood ALL With an iamp21 with an iamp21 compared with other patients with BCP-ALL. According to the highly increased relapse risk, patients with an iamp21 are now assigned into the high-risk arm of the current United Kingdom Medical Research Council (MRC)/CLWP ALL 2003 trial and, in case of a slow early response, are considered for allogeneic stem cell transplantation (SCT) in first complete remission (CR). Because this currently remains the only report of its kind, the extent that the high relapse rate of patients with an iamp21 is influenced by the composition and intensity of the applied treatment, and whether particular parameters may help to predict patients with a low and high risk of relapse, is unknown. We, therefore, report herein our experience with patients with an iamp21 who were enrolled onto the Austrian and German ALL Berlin-Frankfurt-Münster (ALL- BFM) trials. PATIENTS AND METHODS Between September 1986 and January 2007, 1,048 patients with ALL were enrolled onto four Austrian multicenter trials: ALL-BFM 86 (n 142), ALL- BFM 90 (n 256), ALL-BFM 95 (n 230), and ALL-BFM 2000 (n 420). Systematic FISH screening of 885 patient cases (84%) with ETV6/RUNX1- specific probes identified 14 patients (1.6%) with an iamp21. 3,4 An additional 15 patients with an iamp21 were identified in the German ALL-BFM studies. Eleven patient cases were detected by March 2006 (four through FISH confirmation of suggestive karyotypes and seven through retrospective FISH screening of 413 patients), and another four were detected between March 2006 and January 2007, after prospective FISH screening commenced (Table 1). All patient cases were reviewed centrally and were treated after informed consent was obtained from the patient, patient s parents, or the patient s legal guardians. 5 Follow-up was updated in November Studies were conducted with the approval of the responsible ethic committees. Since trial ALL-BFM 90, minimal residual disease (MRD) analysis with polymerase chain reaction based technologies for the detection of clone-specific immunoglobulin and T-cell receptor gene rearrangements was performed after completion of induction therapy (day 33) and early reintensification treatment (day 78). 6-8 However, MRD results were implemented only for risk-adapted stratification in trial ALL-BFM ETV6/RUNX1 analysis was performed with the dual color-labeled LSI ETV6/RUNX1 ES probe set (Vysis, Downers Grove, IL). An iamp21 was defined as the presence of at least five RUNX1 signals in interphase nuclei and/or the colocalization of at least three copies of the RUNX1 gene on a single chromosome 21. Hyperdiploidy was excluded with additional FISH probes in all patient cases with an iamp21. Event-free survival (EFS) and overall survival (OS) rates were analyzed according to the Kaplan-Meier method, and survival curves were compared with the log-rank test. EFS was defined as the time from diagnosis to the first adverse event or to the date of last follow-up. Inability to achieve remission (ie, early death, refractory disease), relapse at any site, death during CR, or the development of a second malignancy were considered adverse events. Patients who failed to achieve CR were assigned a failure time of zero. OS was Patient BFM Study Table 1. Clinical and Laboratory Characteristics and Outcome of the 29 Patients With ALL and an iamp21 on ALL-BFM Trials Age (years) WBC ( 10 9 /L) Phenotype Prednisone Response BM d33 MRD Risk Relapse Time to Relapse (years) Outcome 1 A 86 F call Poor CR NA 1st CR G 86 M call Good CR NA BM 0.94 Died as a result of disease after SCT 3 A 90 F pre-b ALL Poor CR IR BM nd CR (SCT) A 90 M call Good CR IR BM nd CR (SCT) G 90 F call Good CR NA 1st CR A 95 M call Good CR IR BM 2.67 Died as a result of disease 7 A 95 F call Good CR HR BM CNS nd CR (SCT) G 95 F BCP ALL Good CR NA BM nd CR (SCT) G 95 M call Good CR NA BM 2.59 Died as a result of disease after SCT 10 A 2000 F call Good CR LR 1st CR A 2000 F call Good CR IR 1st CR A 2000 F pre-b ALL Good CR LR Died as a result of infection 1st CR 13 A 2000 M call Poor CR LR 1st CR A 2000 M call Good CR IR BM nd CR (receiving therapy) A 2000 F pre-b ALL Good CR LR 1st CR A 2000 F pre-b ALL Good CR IR 1st CR A 2000 M pre-b ALL Good CR IR 1st CR A 2000 F call Good CR IR BM 1.04 Died after SCT in 3rd CR 19 G 2000 F pre-b ALL Good CR IR 1st CR G 2000 M pre-b ALL Good CR IR 1st CR G 2000 M pre-b ALL Good CR IR BM CNS 2.28 Died as a result of disease (after SCT) 22 G 2000 M call Good CR LR 1st CR G 2000 M pre-b ALL Good CR LR 1st CR G 2000 M call Good CR LR 1st CR G 2000 M call Poor CR LR 1st CR G 2000 M call Good CR IR BM 1.62 Died as a result of disease (after SCT) 27 G 2000 F call Good CR LR 1st CR G 2000 M call Good CR IR 1st CR G 2000 F call Good CR IR 1st CR 4.47 Abbreviations: ALL, acute lymphoblastic leukemia; iamp21, intrachromosomal amplification of chromosome 21; BFM, Berlin-Frankfurt-Münster; BM, bone marrow; MRD, minimal residual disease; FU, follow-up; A, Austria; F, female; call, common acute lymphoblastic leukemia; CR, complete remission; NA, not available; M, male; G, Germany; SCT, stem-cell transplantation; IR, intermediate risk; HR, high risk; LR, low risk. FU (years) by American Society of Clinical Oncology 3047
3 Attarbaschi et al defined as the time from diagnosis to death from any cause; for surviving patients, OS was censored at the date of last follow-up. The distribution of categoric variables was analyzed by the 2 test. P values.05 were considered statistically significant. RESULTS Of the 29 patients with an iamp21, two patients were identified in trial ALL-BFM 86, three patients in trial ALL-BFM 90, four in trial ALL- BFM 95, and 20 in trial ALL-BFM 2000 (Table 1). The male-to-female ratio was 15:14, and the median age and leukocyte count at diagnosis were 9.00 years (range, 4.13 to years) and /L (range, 0.7 to /L), respectively. Twenty-five patients (86%) were good responders to prednisone and had less than 1,000/ L blasts after a 7-day prephase with prednisone and one intrathecal dose of methotrexate on day 1. All were in CR after induction therapy. Results on MRD analysis were available in 24 patients (83%). Nine patients (37.5%) were MRD-negative and had two markers at the level of 10 4 after induction therapy (low risk), and 14 patients (58.5%) had levels that were less than after early reintensification therapy (intermediate risk). One patient (4%) fulfilled high-risk MRD criteria ( after early reintensification therapy). Table 2 lists clinical and laboratory characteristics and outcome data of the 29 patients with an iamp21and the 1,596 patient cases without an iamp21. Table 3 lists the data for the 29 patients on ALL-BFM trials compared with the 28 patient cases from the United Kingdom MRC/CLWP. Eleven (38%) of 29 patients experienced relapse after a median time of 2.59 years (range, 0.94 to 5.99 years): one of two patients from trial ALL-BFM 86, two of three from trial ALL-BFM 90, all four from trial ALL-BFM 95, and four of 20 patients from trial ALL-BFM MRD results were available in eight patients who experienced relapse; seven occurred among the 14 intermediate-risk patients, and one occurred in the high-risk patient. Five patients who experienced relapse have survived event-free in second CR after a median follow-up of 4.95 years (range, 0.69 to 7.18 years), which includes four who underwent SCT. Six patients who experienced a relapse died, one as a result of toxicity after SCT in third CR, four as a result of relapse after SCT in second CR, and one as a result of a second relapse after chemotherapy only. Another patient died as a result of an infection in first CR. Median follow-up of the 29 patients was 4.41 years (range, 0.24 to years), but it was less than 1 year in four patients (two each with low and intermediate MRD levels). In the 25 patients with a follow-up of more than 1 year the probabilities of 6-year EFS, relapsefree survival, and OS estimates were 38% 14%, 39% 14% and 66% 11%, respectively (Fig 1). Evaluation of potential prognostic factors (study, sex, age, leukocyte count, prednisone response, MRD levels) among the group of patients with an iamp21 revealed that MRD values were the only parameter able to predict relapsefree survival (MRD low risk [100%] v MRD intermediate risk [37% 16%]; P.02). MRD-based treatment stratification was used for the first time in ALL-BFM 2000, whereas risk assignment in ALL-BFM 86, 90, and 95 was based on conventional parameters only. 4 Conventional and MRD risk group assignment concurred in 19 (79%) of 24 patients. None of the seven patient cases in the MRD low-risk group, but five of 12 in the MRD intermediate-risk group, experienced a relapse. Of the remaining five patient cases, two patients with low MRD risk had a poor response to prednisone and were, thus, assigned to the ALL-BFM 2000 Table 2. Characteristics and Outcomes of Patients With and Without an iamp21 Patients With an iamp21 Patients Without an iamp21 Characteristic No. % No. % P Total No. of patients 29 1,596 Male Female Age, years Median Range , WBC, 10 9 /L Median Range , , NA CNS disease Immunophenotype Pro-B ALL Common ALL Pre-B ALL Other T-ALL NA MRD risk group Low risk Intermediate risk High risk NA Prednisone response Good , Poor NA CR after induction therapy , Relapse Death rate year pefs year pos Abbreviations: iamp21, intrachromosomal amplification of chromosome 21; CNS, central nervous system; ALL, acute lymphoblastic leukemia; MRD, minimal residual disease; CR, complete remission; pefs, probability of event-free survival; pos, probability of overall survival. Analysis was restricted to the 877 patients with minimal residual disease data available. Including mainly patients from trials ALL-BFM 86, 90, and 95, who had not been systematically analyzed for minimal residual disease levels. Data was not disclosed because of the ongoing ALL-BFM 2000 trial; for historical comparison, the treatment results of trial ALL-BFM 95 (N 2,169) were as follows: No. of relapses: 356 (16%); 6-year probability of event-free survival: %; 6-year probability of overall survival: %. 9 Including only patients with a follow-up of more than 1 year. high-risk arm. Both are currently in first CR. The only MRD high-risk patient was treated in the ALL-BFM 95 intermediate-risk group and experienced relapse. Two other patients with MRD intermediate risk were treated according to the ALL-BFM 90 standard-risk and highrisk (poor prednisone response) arm, respectively, but both experienced relapse. However, because the ALL-BFM 90 high-risk arm was by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
4 MRD-Dependent Relapse Risk of Childhood ALL With an iamp21 Table 3. Comparison of the Patients With ALL and an iamp21 Enrolled Onto the BFM and UK MRC/CLWP Studies ALL-BFM Trials (86, 90, 95, 2000) UK MRC/CLWP ALL 97 Trial Characteristic No. % No. % Overall No. of patients with an iamp No. of patients screened 1,625 1,630 % of patients with an iamp Male Female Age, years WBC, 10 9 /L Median CNS disease 0 0 Immunophenotype pro-b ALL 0 0 Common/pre-B ALL T-ALL 0 0 MRD risk grouping Low risk 9 31 NA Intermediate risk NA High risk 1 4 NA NA 5 17 CR after induction therapy Relapse Median time 2.59 NA During front-line therapy After cessation of therapy Death rate Median follow-up, years year pefs, % year pos, % Abbreviations: iamp21, intrachromosomal amplification of chromosome 21; MRC, Medical Research Council; CLWP, childhood leukemia working party; ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Münster; CNS, central nervous system; NA, not available; CR, complete remission; pefs, probability of event-free survival; pos, probability of overall survival. Six-year probabilities of event-free survival and of overall survival were not available for the patients from the United Kingdom study. the only one that contained neither an early reintensification nor a late reinduction element, the survival rates were inferior overall to those achieved in trials ALL-BFM 86, 95, and Of the five patients without MRD data, two were treated according to trial ALL-BFM 86 (one in the standard-risk group who experienced relapsed, and one in the high-risk group with a poor response to prednisone who did not experience relapse), one according to trial ALL-BFM 90 (intermediate risk group without relapse), and two were treated according to trial ALL-BFM 95 (one each from the standard- and intermediate-risk groups who both experienced relapse). These observations support the notion that patient cases with an iamp21 certainly benefit from risk-adapted (on the basis of prednisone response and MRD values) treatment intensifications. Event-Free and Overall Survival censored 6-year EFS: 38 ± 14% 6-year OS: 66 ± 11% Time From Diagnosis (years) Fig 1. Six-year event-free survival (EFS) and overall survival (OS) of the 25 patients with iamp21 with a follow-up of at least 1 year. DISCUSSION Compared with the outcome of the patients in the British study, patients with an iamp21 who are treated according to BFM-based regimens seem to experience a lower overall relapse rate (38% v 61%) and a lower early relapse rate (27% v 47%). In the British cohort, eight (47%) of 17 patients who experienced relapse did so during therapy, and nine (53%) experienced relapse between 8 months and 3 years off therapy. In contrast, in the BFM cohort only three (27%) of 11 patients experienced relapse early, whereas the other eight (73%) experienced relapse after cessation of front-line therapy. Moreover, one of the 28 British patients did not achieve CR at all, and three others were not in CR after induction therapy, whereas all 29 patients enrolled onto BFM trials were in CR at this time point. These differences in the overall and early disease recurrences can most likely be explained by a different effectiveness of various treatment components used in the diverse protocols. 4,10-12 For instance, 20 of 28 British patients received a three-drug (prednisone, vincristine, L-asparaginase) induction, no BFM-type early reintensification (cyclophosphamide, cytarabine, mercaptopurine), and no extracompartment therapy that would include high-dose methotrexate, whereas all three elements were consistent components of the ALL-BFM protocols. 4,10,11 Only eight of 20 British patients received a four-drug (with daunorubicine) induction and subsequent early reintensification therapy with both elements similar to the protracted and intense protocols used by the BFM Group. 4,10,11 However, because the United Kingdom CLWP study did not specify the distribution of the 17 patients who experienced relapse in the two treatment-differing trial periods, this issue cannot be additionally assessed. Nevertheless, even a dose-intensified induction treatment with an additional anthracycline in combination with an early postinduction intensification therapy is insufficient to prevent relapses in a certain proportion of patient cases with an iamp21, because the overall relapse rate was still high, even in the ALL-BFM studies. 2 The combined results of the United Kingdom MRC/CLWP and BFM trials also revealed that 16 of 28 patients who experienced relapse by American Society of Clinical Oncology 3049
5 Attarbaschi et al underwent transplantation, eight (50%) of whom are still in CR after a follow-up time between 4.91 and 7.18 years for the BFM and between 4 months and 3.67 years for the British patient cases. The comparatively good outcome of the British patients who did not undergo transplantation is difficult to interpret, because they were apparently not treated in a systematic fashion and because detailed follow-up data is not available. 2 Nevertheless, along with the continuously improved chemotherapy regimens, allogeneic SCT still remains an alternative treatment option for patient cases with an iamp21 who are in second remission. Although the distribution of patient cases with an iamp21 within the three MRD risk groups resembled that of all other BCP-ALL patient cases, it is worth noting that, except for one patient who was MRD high risk and who experienced relapse, all relapses occurred in patients with a MRD intermediate risk. The average relapse risk for all patient cases in this group is 23%, whereas it translates to 50% (7 of 14) for those with an iamp21. 6 This is, so far, one of the highest predictable relapse risks in a specific genetic childhood BCP-ALL subgroup yet identified. The results of our analysis thus demonstrate not only that MRD values reliably discriminate between patients with an iamp21 who have a low and high relapse risk but also that it is possible to extract and define a specific group of patients with clear and distinct risk features that previously remained concealed in the MRD intermediate-risk group. We conclude that, at least in the context of BFM-based treatment regimens, patient cases with an iamp21 who are MRD low risk have an excellent prognostic outlook and that, for this group, the current type of treatment is sufficient. Conversely, early treatment intensification and assignment to a high risk therapy arm is certainly warranted for those with an intermediate MRD risk. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The authors indicated no potential conflicts of interest. AUTHOR CONTRIBUTIONS Conception and design: Andishe Attarbaschi, Georg Mann, Martin Schrappe, Oskar A. Haas Administrative support: Markus Seidel, Dasa Janousek Provision of study materials or patients: Renate Panzer-Grümayer, Jochen Harbott, Martin Schrappe, Oskar A. Haas Collection and assembly of data: Andishe Attarbaschi, Silja Röttgers, Manuel Steiner, Margit König, Eva Csinady, Dasa Janousek, Anja Möricke, Carsten Reichelt, Jochen Harbott Data analysis and interpretation: Andishe Attarbaschi, Georg Mann, Renate Panzer-Grümayer, Eva Csinday, Michael N. Dworzak, Anja Möricke, Jochen Harbott, Martin Schrappe, Helmut Gadner, Oskar A. Haas Manuscript writing: Andishe Attarbaschi, Michael N. Dworzak, Anja Möricke, Martin Schrappe, Helmut Gadner, Oskar A. Haas Final approval of manuscript: Andishe Attarbaschi, Georg Mann, Martin Schrappe, Helmut Gadner, Oskar A. Haas REFERENCES 1. Harewood L, Robinson H, Harris R, et al: Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: A study of 20 cases. Leukemia 17: , Moorman AV, Richards SM, Robinson HM, et al: Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iamp21). Blood 109: , Attarbaschi A, Mann G, König M, et al: Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1 acute lymphoblastic leukemia: An interphase FISH analysis. Leukemia 18: , Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995: Berlin-Frankfurt-Münster. Leukemia 14: , van der Does-van den Berg A, Bartram CR, Basso G, et al: Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the BFM Family Cooperative Group. Med Pediatr Oncol 20: , van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352: , van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21: , van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, et al: Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-centre setting. Leukemia 21: , Möricke A, Reiter A, Gadner H, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood / blood [epub ahead of print on February 19, 2008] 10. Mitchell CD, Richards SM, Kinsey Se, et al: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129: , Vora A, Mitchell CD, Lennard L, et al: Toxicity and efficacy of 6-thioguanine versus mercaptopurine in childhood lymphoblastic leukemia: A randomized trial. Lancet 368: , Eden OB, Harrison C, Richards S, et al: Longterm follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, : Medical Research Council Childhood Leukemia Working Party. Leukemia 14: , 2000 Acknowledgment The Acknowledgment is included in the full-text version of this article, available online at It is not included in the PDF version (via Adobe Reader ) by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Acute Lymphoblastic Leukemia in Children: A Fifteen Year Experience at the Princess Nourah Oncology Center, Jeddah, Saudi Arabia.
Acute Lymphoblastic Leukemia in Children: A Fifteen Year Experience at the Princess Nourah Oncology Center, Jeddah, Saudi Arabia. 1 Dr. C. Fryer FRCP(C), 2 Dr. S. Felimban FACHARTZ, 3 C. Paltiel MS 4 Dr.
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationTreating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationProject no. 261474 ENCCA. EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS. Network of Excellence. Deliverable Number: 9.
Project no. 261474 ENCCA EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS Network of Excellence Deliverable Number: 9.1 Title: Common guidelines for diagnostic approaches to leukemias Due
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationChildhood and Adolescent Lymphoid and Myeloid Leukemia
Childhood and Adolescent Lymphoid and Myeloid Leukemia Ching-Hon Pui, Martin Schrappe, Raul C. Ribeiro, and Charlotte M. Niemeyer Remarkable progress has been made in the past decade in the treatment and
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationAcute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationSonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationBiometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren
Biometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren Dipl.-Math. C. Sauerland (sauerla@uni-muenster.de) Dipl.-Biomath. S. Amler
More informationStakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development
More informationGuideline for the Management of Acute Lymphoblastic Leukaemia (ALL) in Adults
Guideline for the Management of Acute Lymphoblastic Leukaemia (ALL) in Adults Version History Version Date Summary of Change/Process 1.0 The UKALL trial protocol was approved as version 1. 1.1 22.07.10
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationGeneral Discussion Summary Recommendation Samenvatting Intisari
9 General Discussion Summary Recommendation Samenvatting Intisari General Discussion Summary Recommendation 169 9 General Discussion Summary Recommendation Samenvatting Intisari 170 Diagnostic Advances
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationPediatric Ph + ALL. Andrea Biondi, MD on behalf of the I-BFM EsPhALL group
The EsPhALL experience for the treatment t t of Pediatric Ph + ALL Andrea Biondi, MD on behalf of the I-BFM EsPhALL group Clinica Pediatrica, Centro M.Tettamanti and Dipartimento di Scienze della Salute,
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationWhy discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationSurvival from acute non-lymphocytic leukaemia, 1971-88: a population based study
Archives of Disease in Childhood 1994; 70: 219-223 Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study 219 C A Stiller, E M Eatock Childhood Cancer Research Group, University
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationJ Clin Oncol 28:648-654. 2009 by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 4 FEBRUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Therapeutic Advances in Childhood Leukemia Consortium, Institute for Pediatric Clinical Research and
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationDNA Methylation in MDS/MPD/AML: Implications for application
DNA Methylation in MDS/MPD/AML: Implications for application James G. Herman, M.D. Professor of Oncology Evelyn Grollman Glick Scholar The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Disclosures
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationCytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Executive Summary Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world, but is significantly less frequent in Asia. The median age of
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationRisk Stratification in AML. Michelle Geddes Feb 27, 2014
Risk Stratification in AML Michelle Geddes Feb 27, 2014 Objectives Outline the challenges in post-remission therapy for AML Review etiology of disease escape mechanisms from therapy Evaluate prognostic
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-Based Gene Expression Profile Testing for Multiple File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_profile_testing_for_multiple_myeloma
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationSurvival Rate of Childhood Leukemia in Shiraz, Southern Iran
Original Article Iran J Pediatr Feb 23; Vol 23 (No ), Pp: 5358 Survival Rate of Childhood Leukemia in Shiraz, Southern Iran AlmasiHashiani, Amir, MSc; Zareifar, Soheil 2, MD; Karimi, Mehran 2, MD; Khedmati,
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationAcute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
More informationEmerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
More informationCancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationIn ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior
- First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti
More informationAcute Lymphoblastic Leukemia in Adults and Children
Acute Lymphoblastic Leukemia in Adults and Children Session Chair: Charles Linker, MD Speakers: Stephen E. Sallan, MD; Nicola Gökbuget, MD; and Ching-Hon Pui, MD Myths and Lessons from the Adult/Pediatric
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More informationHaematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation
Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology
More informationHematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of highdose chemotherapy for breast cancer patients Marino P, Siani C, Roche H, Moatti J P Record Status This is a critical
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationLife Tables. Marie Diener-West, PhD Sukon Kanchanaraksa, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationAcute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary?
Progress in Hematology International Journal of HEMATOLOGY Acute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary? Thomas Büchner, a, * Wolfgang Hiddemann, b Bernhard Wörmann,
More informationAML: How to characterize and treat elderly patients non fit for standard chemotherapy
m1 AML: How to characterize and treat elderly patients non fit for standard chemotherapy Clinic for Medicine III University Hospital Munich Campus Grosshadern AMLCG study group Karsten Spiekermann, MD
More informationEvaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación
More informationUMHS-PUHSC JOINT INSTITUTE
Imaging Biomarkers for Staging and Assessing Response to Therapy in Multiple Myeloma Qian Dong, MD. Radiology University of Michigan Wei Guo, MD. Orthopedic Oncology Peking University Second Hospital Team
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationChronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation
Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationNovità dall EHA >> [ Leucemia linfatica cronica ]
Novità dall EHA >> [ Leucemia linfatica cronica ] Relatore: P. GHIA 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia linfatica cronica - Copyright FSE 1 Number and type of abstracts 2 Number
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationA Career in Pediatric Hematology-Oncology? Think About It...
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationPractice of Interferon Therapy
Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationNew Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the
More informationHow To Treat Leukaemia With Cord Blood Stem Cell
Cord blood for the treatment of acute lymphoblastic leukemia in young children By Caitlin McGreevy Kiara Paramjothy Pass with Merit RESEARCH PAPER BASED ON PATHOLOGY LECTURES AT MEDLINK 2011 1 Abstract:
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationHealth Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationCyrine-Eliana Haidar, Pharm.D., BCPS, BCOP; and Jennifer L. Pauley, Pharm.D., BCPS
Pediatric Leukemias Cyrine-Eliana Haidar, Pharm.D., BCPS, BCOP; and Jennifer L. Pauley, Pharm.D., BCPS Reviewed by Betsy Bickert Poon, Pharm.D.; Todd P. Semla, Pharm.D., M.S., FCCP, BCPS, AGSF; and Maya
More information